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In 16 depression clinics in hospitals and outpatient facilities in the Netherlands, a study was performed to evaluate and compare 
the efficacy and tolerability of citalopram and fluvoxamine and to determine the difference in the incidence of gastrointestinal 
side-effects. A total of 217 patients with a depressive disorder (DSM-111-R criteria) and a score of at least 16 on the Hamilton 
rating scale for depression were randomized to treatment. The results of this study indicate that the two drugs are equally 
effective. The adverse events occuring during treatment show a similar pattern between the two drugs, but citalopram is better 
tolerated than fluvoxamine. Citalopram induces fewer gastrointestinal adverse events compared with fluvoxamine. However, this 
did not affect the drop-out rates. 
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INTRODUCTION 
The involvement of serotonin (5-HT) in the develop-
ment of depressive disorders was first postulated 
about 25 years ago (Lapin and Oxenkrug, 1969). 
Since that time, laboratory studies and studies in 
depressed patients, post-mortem studies and the clin-
ical use of serotonin precursors have supported the 
involvement of serotonin in the development of 
depressive illness (Curzon, 1982). Many drugs used 
as antidepressant treatments potentiate serotonin 
transmission, which resulted in the suggestion that 
depression is correlated with a serotonin deficiency 
syndrome (Asberg et al., 1986). 
The group of drugs which specifically inhibit sero-
tonin uptake appear to be the most clinically useful 
(Burrows, et al., 1988) and are as effective as standard 
© 1996 Rapid Science Publishers 
tricyclics (Bech and Cialdella, 1992). Although no 
clinical evidence has emerged to suggest that these 
drugs are more effective or have a faster onset of 
action than the older, tricyclic antidepressants, the 
major advantage of the SSRis (selective serotonin 
reuptake inhibitors) appears to be a relative lack of 
anticholinergic effects and as a consequence a lack of 
cardiovascular toxicity in overdose (Leonard, 1988). 
Furthermore they lack sedative properties, making 
them more suitable for use in ambulant patients 
(Montgomery, 1988). This potential improvement 
in therapeutic effect may represent an important 
advance in the treatment of depression (Montgomery, 
1989). 
Fluvoxamine is a SSRI which has been in clinical 
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use in the Netherlands for some years. The anti-
depressant efficacy of fluvoxamine has been shown to 
be comparable to that of tricyclic antidepressants, but 
as expected, it presents a different profile of side-
effects (Burrows et a/., 1988). Despite the low inci-
dence of adverse anticholinergic effects, fluvoxamine 
does cause, in about one-third of the patients, a high 
incidence of gastrointestinal side-effects such as nau-
sea and vomiting (Benfield and Ward, 1986; Bateman 
and Chaplin, 1988). 
Citalopram is the most selective SSRI marketed 
(Hyttel, 1982, 1988, 1993; Hyttel and Larsen, 1985). 
The efficacy of citalopram has been established in 
placebo-controlled studies both in the long and short 
term (DUAG, 1986; Gravem et al., 1987; Timmer-
man et al., 1987; Bech and Cialdella, 1992; Mont-
gomery, et al., 1992; Nyth et al., 1992; Silverstone, 
1992) at doses between 20 mg and 60 mg/day. It 
causes few anticholinergic and cardiovascular side-
effects. Like other SSRis, gastrointestinal symptoms 
seem to be the most frequently observed side-effects. 
Clinical trial data on citalopram suggest the incidence 
of nausea to be about 20% (Dencker and H0pfner 
Petersen, 1988). 
Although superior efficacy has not been demon-
strated for any of the SSRis, the structural diversity 
of this group is reflected in emerging qualitative and 
quantitative differences in side-effects and drug inter-
action potential (Lane eta/., 1995). Thus, this study 
was designed to compare and contrast the efficacy 
but more specifically the tolerability of citalopram 
with fluvoxamine in outpatients with a major depres-
sive disorder. The tolerability recording had special 
emphasis on the incidence of gastrointestinal side-
effects, such as nausea and vomiting. 
METHODS 
Design 
This was a 6-week, double-blind, multicentre, ran-
domized parallel group comparison of citalopram 
and fluvoxamine in outpatients with a major depres-
sion according to DSM-III-R criteria. 
The selected outpatients were attending 16 depres-
sion clinics in hospitals or other outpatient facilities 
in the Netherlands. These patients were randomly 
assigned to double-blind treatment with either citalo-
pram or fluvoxamine. The treatment period was 6 
weeks. The starting dose was either 20 mg of citalo-
pram or I 00 mg of fluvoxamine. Both treatments 
were to be taken once a day in the evening. After 1 
week the dosage was to be increased to 30 mg of 
citalopram (once a day, in the evening) or 150 mg of 
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fluvoxamine (50 mg at noon and 100 mg in the even-
ing). These dosage regimes were to be continued for 3 
weeks, thus completing the 4-week, fixed-dose treat-
ment regime. After the 4-week treatment period, the 
dosage was either continued at the same level, or in 
case of insufficient response, increased to 40 mg of 
citalopram (once a day, in the evening) or 200 mg of 
fluvoxamine ( 100 mg at noon and 100 mg in the even-
ing; the advised therapeutic dose in the Netherlands 
in 1992, range 100-200 mg/day). The selected dose 
was then continued for a further 2 weeks thus com-
pleting the 6 weeks of study treatment. The original 
fluvoxamine and citalopram tablets were packed into 
identical capsules. Placebo capsules were used to 
ensure that the same number of capsules were 
received in each treatment group. Patients attended 
for assessment at the beginning of the study and after 
I, 2, 4 and 6 weeks on study treatment. At each visit, 
the Clinical Global Impressions (CGI; Guy, 1976), 
Hamilton depression rating scale (HAMD; Hamil-
ton, 1967; Bech eta!., 1989) and the UKU side-effect 
rating scale (Lingjaerde et al., 1987) were to be 
assessed. The patients were asked to complete the 
Zung self-rating depression scale (20 items; Zung, 
1965; Dijkstra, 1974; Zitman et al., 1989) just prior to 
the entry visit and during the treatment period just 
prior to each visit after I, 2, 4 and 6 weeks. 
Patients 
Cooperative outpatients of either sex with a reason-
able knowledge of the Dutch language and aged 
between 18 and 70 years, who met the DSM-III-R 
criteria for (i) major depression, single episode 
(296.2), (ii) major depression, recurrent (296.3), or 
(iii) bipolar disorder, depressed (296.5), with a score 
of at least 16 on the HAMD (17 items) and after 
having given written informed consent, were eligible 
for the study. Excluded were patients who had been 
treated with monoamine oxidase (MAO) inhibitors 
or fluoxetine within the last 3 weeks or with other 
psychotropic drugs within the last week, with the 
exception of benzodiazepines. Furthermore, patients 
with another primary psychiatric diagnosis than the 
above mentioned, or with a history of epilepsy, alco-
hol and/or drug abuse, pregnant or lactating women 
and women of childbearing potential failing to use 
standard birth control methods, as well as patients 
wtth renal, hepatic, cardiovascular, neurological or 
somatic disorders, and/or significant abnormal 
laboratory findings, were excluded. 
Assessments 
The primary efficacy variable was the 17-i tern Hamil-
ton depression rating scale total score (HAMD). As 
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secondary efficacy variables, the Clinical Global 
Impression (CGI, severity of illness), the Zung Self-
rating Scale for Depression, the HAMD factors and 
the HAMD total score (50% reduction of baseline 
score) were used. Severity of adverse events and the 
influence of these events on daily functioning were 
assessed by means of the UK U side-effect scale (0 = 
none, 1 = mild, 2 = moderate, 3 = marked; Lingjaerde 
et a!., 1987; Kamp and Haffmans, 1989). Spon-
taneously reported adverse events were also recorded. 
Clinical laboratory tests and physical examinations 
were carried out at the beginning and end of the 
study treatment period. Physical examinations 
included body weight, height, blood pressure and 
heart rate. Selected benzodiazepines as permitted 
concomitant medication at baseline could be con-
tinued during the study. Patients who were receiving 
other benzodiazepines were switched to one of the 
following permitted drugs. The maximum doses of 
the benzodiazepines which could be given during the 
study were: oxazepam at 50 mg daily, lormetazepam 
at 4 mg daily, temazepam at 20 mg daily, lorazepam 
at 4 mg or flurazepam at 15 mg daily. Preferably, the 
daily dosage was stable during the study period. All 
non-psychotropic medication was allowed but the 
regime was to be kept stable. In case of severe nausea 
and/or vomiting, domperidone could be given. 
Joint rating sessions were held at an investigator 
meeting before the start of the study and at three 
investigator meetings during the study. The interrater 
reliability was> 0.80. 
The study was performed in accordance with the 
Declaration of Helsinki. The study was approved by 
the appropriate institutional review board and ethics 
committee. 
Statistical considerations 
Sample size and study power 
A prospective sample size estimate was made, which 
had a priority of assessing the between-group com-
parisons of side-effects for citalopram and fluvoxam-
ine treatment groups. The hypothesis to be tested was: 
citalopram would give a 50% lower incidence of gas-
trointestinal side-effects in comparison with fluvox-
amine at the equivalent level of efficacy. Statistical 
significance was to be assessed at the 5% level (p = 
0.05) using two-tailed tests. The study design chosen 
with a specific side-effect questionnaire was expected 
to give a relatively high incidence of reported side-
effects. The side-effect reporting expected with flu-
voxamine was 35% and required a sample size of 115 
patients in each treatment group (in total 230 
patients) to detect with an 80% power (1 - fJ = 0.80) 
and an alpha of 0.05 (a = 0.05) for the difference 
between the two treatment groups. 
Analysis population 
The intention-to-treat population {ITT) included all 
patients who had been allocated a randomization 
number on entry of double-blind treatment. 
Specific statistical procedures 
The ordered categorical data (e.g. HAMD, CGI) 
were analysed using the Cochran-Mantel-Haenszel 
test, with modified scores that allow adjustment for 
baseline differences where appropriate. Confidence 
intervals for the treatment difference were calculated 
using a non-parametric method (Armitage and Berry; 
Statistical Methods in Medical Research, third edn, 
in press). Two-by-two tables (e.g. improved/not 
improved) were analysed using either the x2 test or 
Fisher's exact test, depending upon the characteristics 
of the data. 
The Zung score has been summarized in a similar 
manner to that suggested by Zung (1965). The Zung 
score was not to be used to investigate the difference 
between the efficacy of the two treatment groups, but 
to determine whether the patient's assessment of effi-
cacy was related to that of the investigator. The 
analysis of the Zung index included tests for a correl-
ation with the HAMD and CGI scores, using Pear-
son and Spearman rank correlation methods. 
Multiple regression methods, with entry and dele-
tion levels set at 0.1, were used to examine the effects 
of the following covariates on the total HAMD 
score: centre, age, sex, previous psychiatric history, 
severity at entry, gastrointestinal (GI) adverse events. 
RESULTS 
Patients 
Between May 1990 and July 1992, a total of 217 
patients were entered into the study. One hundred 
and eight patients ( 45 M, 63 F; median age 44.2 
years) were randomized to citalopram and 109 
patients ( 44 M, 65 F; median age 40.2 years) to 
fluvoxamine. 
Approximately 60% of the patients had a history 
of clinically significant somatic disorders and about 
half of them had a family history of psychiatric 
disorders. Forty-six out of 108 patients treated with 
citalopram and 59 out of 109 patients treated with 
fluvoxamine had experienced a previous depressive 
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TABLE 1. Psychiatric data on the current depressive episode (n = 217) 
ITT Efficacy 
Citalopram Fluvoxamine Citalopram Fluvoxamine 
(n = 80) Current (n= 108) 
Severity 
Mild 3 
Moderate 38 
Severe 
{i) without psychotic features 66 
{ii) with psychotic features 1 
DSM-111-R diagnosis 67 
Major depression single episode 296.2 
Major depression recurrent episode 296.3 38 
Bipolar disorder (depressed) 296.5 3 
Duration (weeks) 
Median 26 
Range 3-400 
Antidepressant treatment received within 70 
3 weeks of starting study (no. of patients) 
episode. A summary of the diagnosis, according to 
the DSM-111-R classification, as well as the severity, 
duration and treatment of the current depressive 
episode is presented in Table I. The depressive episode 
was assessed as severe in about 60% of the patients. 
Approximately 60% of the patients were receiving 
treatment for their depression at the start of the trial, 
and most patients had responded poorly. The 
intention-to-treat population (ITT) consisted of all 
217 patients. Twenty-one patients treated with citato-
pram and 29 treated with fluvoxamine were with-
drawn from the study due to adverse events (n = 15; 
13.9% and n = 23; 21.1%, respectively), non-
compliance (n = 4; 3.7% and n = 3; 2.8% respectively) 
and unallowed comedication (n = 2 and n = 3). These 
50 patients were excluded from the ITT sample for 
the efficacy analysis. There was no significant differ-
ence between the treatment groups when the reasons 
for withdrawal were examined. Similarly, analysing 
time to withdrawal, no significant differences between 
the two treatment groups emerged. 
A total of 69 patients in the citalopram group and 
65 in the fluvoxamine group received the higher doses 
during the last 2 weeks. Of the patients who com-
pleted the 6-week, double-blind study, 57 patients of 
the citalopram group and 46 patients of the fluvox-
amine group continued treatment. In addition, four 
patients on citalopram and one patient on fluvoxam-
160 International Clinical Psychopharmacology· Vol II· 1996 
(n= 109) (n = 87) 
1 3 1 
45 30 33 
60 53 44 
3 1 2 
54 54 44 
52 30 34 
3 3 2 
26 26 34,5 
2-312 3-400 2-312 
80 57 55 
ine, who did not complete the 6-week trial period, 
continued treatment. 
Benzodiazepines were given to 18 (17%) patients 
on citalopram and 24 (22%) patients on fluvoxamine. 
The difference between the groups is not statistically 
significant. The antiemetic agent domperidone was 
given to 10 (9%) of the citalopram group and 23 
(21%) of the fluvoxamine group. The difference is 
significant (p = 0.02, x2 test). 
Efficacy 
The primary efficacy variables was the HAMD total 
score. All patients had a HAMD total score of at 
least 16 at entry into the trial. In Table II, the data 
show a substantial decrease of the total score in both 
treatment groups during the study. The mean total 
score dropped from about 25 at baseline to approxi-
TABLE II. HAMD total scores at baseline and after 2, 4 
and 6 weeks of treatment with citalopram or fluvoxamine 
Citalopram Fluvoxamine 
Mean Range Mean Range 
Baseline 24.7 17-35 24.5 17-38 
Week2 21.2 5-38 22.3 5-39 
Week4 19.0 4-39 20.0 2-39 
Week6 16.6 2-38 18.0 2-39 
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TABLE Ill. Number of complete and partial responders 
and non-responders after 6 weeks of treatment 
HAMD score Citalopram Fluvoxamine 
(n= 108) (n=109) 
Q-7 15 9 
8-15 30 34 
>15 63 66 
mately 17 at week 6. There were no significant differ-
ences between the two treatments. 
In Table III the number of patients showing com-
plete response (HAMD total score 0-7), partial 
response (HAMD total score 8-15), and non-
response (HAMD total score greater than 15) at 
week 6, are presented. Two patients in the fluvoxam-
ine group could not be included in this analysis 
because of missing data. Fifteen citalopram patients 
(14%) and 9 fluvoxamine patients (8%) showed com-
plete response. The difference is not significant. The 
mean percentage reduction in score at week 6 was 
33% in the citalopram group and 26% in the fluvox-
amine group. Thirty-three out of 108 patients on cita-
lopram and 31 out of I 09 patients on fluvoxamine 
showed a reduction in total score of 50% or more. 
Multiple regression revealed that there was a sig-
nificant difference between centres and showed that 
the final HAMD total score was closely related to 
gastrointestinal adverse events, baseline HAMD 
total score and age. No relation was found between 
the final HAMD score and psychiatric history or sex. 
There was no indication of a treatment difference 
(p > 0.01). 
HAMD factors (Table Ill) 
The mean scores between baseline and at week 6 of 
the HAMD factor scores show a clear reduction in 
melancholia, retardation and anxiety/somatization 
for both treatment groups. The difference between the 
TABLE IV. Differences in incidence of adverse events-
excess incidence versus comparator 
Symptom 
Diarrhoea 
Nausea 
Vomiting 
Tachycardia 
Tremor 
Paraesthesia 
Suicide attempt 
Citalopram 
% 
+10.4 
Fluvoxamine 
% 
+ 13.6 
+ 16.0 
+ 9.1 
+ 10.8 
+ 11.7 
+ 4.6 
groups was not statistically significant. The sleep 
disturbance factor scores were also reduced in both 
treatment groups during the 6-week study, but less 
markedly as for the other factors. 
Clinical Global Impression (CGI) 
At baseline the majority of patients scored 3 or 4 
(moderately ill). At the end of the study, 37 of the 
citalopram group (34%) and 35 of the fluvoxamine 
group (32%) and 35 of the fluvoxamine group (32%) 
had score 1 (no illness/mild illness). The analysis of 
severity of illness score at end-point, adjusting for 
baseline score, showed a median difference between 
treatment groups of -0.26 with 95% confidence inter-
val, -0.64 to 0.11 (p = 0.13). 
Zung self-rating depression scale 
For each visit the patients completed the Zung self-
rating depression scale. The mean indices at baseline 
were very similar in the two treatment groups, and the 
values decreased during the 6-week trial period in 
both groups. A correlation analysis showed a highly 
significant correlation between the Zung indices, the 
HAMD scores and the CGI scores for the week 6 
data, with Pearson correlation coefficients of 0. 73 
and 0.65, respectively. 
Tolerability (Table IV) 
The objective behind using the UK U side-effect rat-
ing scale in this trial was to allow a more accurate 
comparison of the most critical complaints made by 
patients when treated with 5-HT uptake inhibitors. 
As expected, at baseline, a high incidence of 'side-
effects' was reported (spontaneously reported and 
UK U scores) by 57% of the patients. 
The incidence of treatment-emergent diarrhoea 
was higher in patients receiving fluvoxamine (p = 
0.026) as was the incidence of nausea (p = 0.017). 
Furthermore, there was a trend towards a higher 
incidence of vomiting in the fluvoxamine group (p = 
0.052; Table V). 
The incidence of diarrhoea at the end of the study, 
after dose increment for many patients, was similar 
for citalopram and fluvoxamine with eight mild 
reports in each group corresponding to an incidence 
of 7.4% and 7.3%, respectively. In contrast, the inci-
dence of nausea remained higher on fluvoxamine 
throughout the study period, confirming a clinically 
important difference. Mild nausea was reported in 
eight and twelve patients and moderate nausea in one 
and six patients for citalopram and fluvoxamine, 
respectively. At week 6 vomiting was only recorded in 
the fluvoxamine group. 
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TABLE v. Incidence and course of the main side-effects in percentages after 1, 2, 4 and 6 weeks of treatment with 
citalopram (Cit) or fluvoxamine (Flu) 
Cit Flu Cit 
% % % 
Nausea 25.0 34.8 23.1 
Headache 14.8 14.7 11.3 
Tachycardia 10.2 12.0 5.5 
Paraesthesia 11.1 7.3 7.4 
Vomiting 7.4 11.9 
Diarrhoea 9.3 13.7 6.5 
Tremor 11.1 29.2 12.0 
Serious adverse events 
Four serious adverse events were reported in patients 
treated with citalopram. These included suicide (n = 
1 ), a fatal myocardial infarction (n = I), a diagnosis 
of multiple sclerosis whilst continuing citalopram 
treatment (n = I) and a pregnancy {n = l ). Six serious 
adverse events were reported for the fluvoxamine 
group. These included suicide attempts (n = 2), sui-
cidal tendencies (n = 2), aggressive reaction and agita-
tion in a psychotic patient (n = I) and aggravation of 
depression (n = I), all resulting in hospitalization. 
The causal relationship to test treatment was in all 10 
cases assessed as either no relationship or unlikely. 
UKU, assessment of adverse events 
At baseline, about 50% of the patients had adverse 
events with either moderate or marked interference 
with daily functioning (score 2 or 3). After 1 week of 
treatment, the percentages of patients with scores 2 
or 3 remained constant in the citalopram group, 
whereas the percentage of patients with score 3 was 
almost doubled in the fluvoxamine group. Later in 
the trial period, the relative number of patients with 
score 3 decreased in both treatment groups. 
Safety results 
Concerning the vital signs data or laboratory data, no 
obvious differences between the treatment groups 
could be detected, either at entry or end-point and no 
changes were seen over the duration of the study. 
DISCUSSION 
Most newer antidepressants induding the SSRis 
have been compared with the tricyclic antidepres-
sants, but few comparative studies of two different 
SSRis have been published (Lane et al., 1995). This 
report describes the results of a comparative clinical 
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2 
Week 
4 6 
Flu Cit Flu Cit Flu 
% % % % % 
30.2 17.6 20.1 8.3 16.5 
15.6 14.0 14.9 7.3 11.1 
10.3 7.4 11.9 5.6 7.3 
5.5 4.6 4.6 5.6 4.7 
0 1.8 0 4.6 
11.9 5.6 15.6 7.4 7.3 
17.5 9.3 13.8 4.6 11.1 
trial of the two SSRis citalopram and fluvoxamine. 
The aim of the trial was to compare the efficacy and 
specifically the tolerability of the two antidepressant 
drugs in a double-blind, parallel group study with 
flexible dose-ranges within the ranges recommended 
by the manufacturers of the two drugs. 
The demographic characteristics were similar in the 
two groups. It is remarkable that the median duration 
of the present depressive episode in both groups was 
26 weeks with a range of 3 weeks to 8 years in the 
citalopram group and 2 weeks to 6 years in the flu-
voxamine group. The efficacy of treatment using the 
HAMD, the CGI severity of illness, and the Zung 
self-rating depression scale indicated that the 
response rate was rather low. The reason for this poor 
response may be related to the fact that many of the 
patients had a long duration of their present episode 
as mentioned above (Scott et al., 1992) and 60% of 
the patients were receiving unsuccessful antidepres-
sant therapy before entry into the study, indicating a 
possible therapy resistance (Guscott and Grof, 1991). 
Other reasons may be the short duration of the trial 
(6 weeks) in combination with the slow increment of 
the dosage and the fact that the patients were not 
treated with the currently accepted maximal dosages 
of the SSRis (fluvoxamine 300 mg/day; citalopram 
60 mg/day). However, no rationale for this variability 
in dosage could be determined, as moderate dosages 
of approximately 150 mg/day or 40 mg/day were 
shown to be effective in the treatment of depression 
(Kaspar et al., 1992). Furthermore, there are more 
patients in the fluvoxamine group who are treatment 
resistant and have a longer duration of their current 
depressive episode. 
The results of the ratings on the HAMD total 
score, HAMD factors and the Zung self-rating scale 
were supported by the global ratings, which showed 
that about one-third of the patients in each group 
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had a score of 0 or 1, indicating no depression or 
only mild depression at end-point. The finding that 
the sleep disturbance factor was less markedly 
reduced might be explained by the fact that SSRis 
are not sedative. 
The severity of the depression at entry as well as 
the relatively small sample size and the lack of a pla-
cebo control group might limit the conclusions on the 
efficacy results. However, the sample size was esti-
mated on the main purpose of this study, i.e. to com-
pare the type, severity and frequency of the adverse 
events. 
Adverse events were recorded by using the UK U 
side-effect rating scale (Lingjaerde et al., 1987). The 
incidence of adverse events was recorded at baseline 
and, as expected, many adverse events were assessed. 
The comparison between treatments comprised 
treatment-emergent adverse events defined as adverse 
events not present at baseline or, that recur, with at 
least one visit without the adverse event. 
A significantly higher incidence of diarrhoea and 
nausea was recorded in patients receiving fluvoxam-
ine. In addition, there was a definite trend that vomit-
ing was seen more frequently in the patients in the 
fluvoxamine group than in the citalopram group. This 
is in good agreement with the fact that significantly 
more patients in the fluvoxamine group were pre-
scribed the antiemetic drug domperidone. Domperi-
done has peripheral antidopaminergic activity and 
crosses the blood-brain barrier only to a limited 
extent. 
The recording of adverse events per assessment 
point showed that nausea and vomiting were 
reported most frequently at the beginning of treat-
ment, particularly in the citalopram group. Although 
citalopram has a higher serotonin affinity, these dif-
ferences in side-effects might be due to the different 
selectivity of serotonin reuptake inhibition. In this 
outpatient study, dosages of fluvoxamine and citato-
pram were chosen at a maximum of 200 mg/day and 
40 mg/day, respectively. Higher initial dosages of flu-
voxamine resulted in an increased incidence of 
adverse effects without any concomitant improve-
ment (Kaspar et at., 1992). A lower initial dose of 
fluvoxamine ( < 100 mg) might have resulted in less 
initial side-effects. 
Tachycardia is a known adverse reaction of tri-
cyclic antidepressants, but is uncommon in patients 
treated with 5-HT uptake inhibitors. The incidence 
of tachycardia in this study was surprisingly high 
(citalopram 20.4% and fluvoxamine 31.2%), maybe as 
a somatic symptom of anxiety. The difference 
between treatments did not reach the level of stat-
istical significance. 
Symptoms classified as paraesthesia were recorded 
slightly, but not significantly, more frequently in 
patients receiving citalopram than in patients receiv-
ing fluvoxamine, whereas the incidence of tremor 
tended to be higher in the fluvoxamine group. 
Suicide or suicide tendencies is a niche of special 
interest in clinical trials in depression. Suicide attempt 
(WHO preferred term) was recorded in I out of !08 
patients on citalopram and in 6 out of I 09 patients 
on fluvoxamine. Due to the very small numbers, this 
finding may be incidental. 
CONCLUSION 
The results of this double-blind comparative study of 
citalopram and fluvoxamine indicate that the two 
SSRis are equally effective. In the population of 
patients entered into the study, the response rate in 
both treatment groups was rather low. The adverse 
events occurring during treatment show a similar pat-
tern between the two drugs at these dosages, in favour 
of citalopram. 
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